-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the addition of a Class 1 innovative drug independently developed by the company and China's first ultra-long-lasting original dual-target emetic injection with phosphorapitamparonosetron for injection.
Share
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the addition of a Class 1 innovative drug independently developed by the company and China's first ultra-long-lasting original dual-target emetic injection with phosphorapitamparonosetron for injection.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending